Jump to content

redpencil

Member
  • Posts

    422
  • Joined

  • Last visited

redpencil's Achievements

Newbie

Newbie (1/14)

0

Reputation

  1. CSL, on an expansion sweep, opens operations in Russia December 8, 2015 | By Eric Palmer Australia's CSL has been expanding around the world and now has taken its U.S.-based blood plasma business, CSL Behring, into Russia. It is following other pharma companies that are looking for growth there. The company said today it has opened operations in Moscow, and is looking for ways to partner up with the government on projects there. CEO Paul Perreault said it may be possible to transfer CSL Behring's plasma collection technology to Russia, according to a statement, and added he can see a point at which the firm might set up some of its plasma collection technology in Russia, and even manufacturing there. CSL Behring makes protein-based therapies for the treatment of bleeding disorders like hemophilia, immune deficiencies, inherited respiratory disease and hereditary angioedema. Perreault said having an office there will allow the company to get a better feel for just what Russia needs. He noted that Russia's per capita use of immunoglobulins is 10 to 20 times lower than in the U.S. and some European countries, an indication that opportunity abounds. http://www.fiercepharma.com/story/csl-expa...ssia/2015-12-08
  2. "Banks and miners beware. Healthcare stocks could replace you as the next generation of blue chip stocks, as CSL becomes the first stock tipped to top $100. CSL is set to be the first currently traded stock to break $100, says Goldman Sachs, which has slapped a $107 price target on the stock........................................." Read more: http://www.smh.com.au/business/markets/cou...l#ixzz3TZrQ4xv2
  3. Thank you Wolverine. I wish I could reciprocate. BTW bought the other innovative Aussie health care stock to do well, CST, and made a packet out of them too. Would have been more if the directors had stuck to their word.
  4. CSL listed in 1994 at $2.30. 3/1 split a few years ago. Now $90 (i.e $270 equiv with split) That's a 120 bagger. Best financial decision I ever made to invest 20 years ago. This year will see $100 SP. Falling $AU can only help. Don't think Cash is King here. Would rather it be in health care. Look at price of COH and RHC over the last few months.
  5. I don't understand why anyone is buying at these prices. NAB and ANZ are paying about 5.5% fully franked div compared to 4.5% for CBA. On top of this surely lower interest rates mean lower bank profits in the short term?
  6. From PR Newswire 29_10_14 What a shame we didn't hang on to it. Red Red
  7. Novartis deal makes CSL second biggest flu vax supplier. The stock that keeps on giving. Now up 50% in 2 years. see also https://au.finance.yahoo.com/news/csl-looks...-011709625.html "The blood plasma products and vaccine maker's chief executive on Monday reiterated that the company was working with the Bill and Melinda Gates Foundation and the World Health Organisation on developing a treatment for the disease that so far has killed more than 4,500 people in the latest outbreak. CSL is not directly working on a vaccine, but is investigating developing "hyper immune" blood plasma products to treat it. Kent Brantly, a US doctor who contracted Ebola in Africa and survived, reportedly has helped save the lives of three Americans by donating his blood plasma containing antibodies. "(What CSL is doing) is similar to the medical effect that you might have seen in the US," CSL chief Paul Perreault told reporters. "You collect plasma from Ebola patients that have recovered from Ebola, try to collect their plasma and then manufacture specialised hyper immune products that can be delivered back into patients." CSL already employed those types of "hyper immune" products to treat tetanus and rabies, he said." Red
  8. CSL starting to look cheap again, based on positive predictions: http://www.northforkvue.com/finance/26601/...tsche-bank-csl/ CSL Limited Rating Reiterated by Deutsche Bank (CSL) December 18th, 2013 CSL Limited (ASX:CSL)‘s stock had its “buy†rating restated by equities researchers at Deutsche Bank in a research report issued on Monday, Analyst Ratings Net reports. CSL Limited (ASX:CSL) opened at 66.210 on Monday. CSL Limited has a 52 week low of A$51.690 and a 52 week high of A$69.755. The stock’s 50-day moving average is A$67.84 and its 200-day moving average is A$65.03. The company has a market cap of A$32.268 billion and a price-to-earnings ratio of 27.31. A number of other firms have also recently commented on CSL. Analysts at JPMorgan Chase & Co. reiterated an “overweight†rating on shares of CSL Limited in a research note to investors on Sunday, November 24th. They now have a $70.70 price target on the stock. Separately, analysts at Bank of America Corp. reiterated a “buy†rating on shares of CSL Limited in a research note to investors on Friday, November 15th. They now have a $71.80 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. CSL Limited currently has a consensus rating of “Hold†and a consensus price target of A$71.25 ($63.62)." Cheers
  9. net profit up by 33%, cash profit by 9.3% depends on which one you like most Net profit rose 33.6 per cent to $5.45bn after a bad debt-plagued prior year, but analysts tend to focus on cash profit as it smoothes out one-offs. - See more at: http://www.theaustralian.com.au/business/p...h.NZDul4Uv.dpuf Net profit rose 33.6 per cent to $5.45bn after a bad debt-plagued prior year, but analysts tend to focus on cash profit as it smoothes out one-offs. - See more at: http://www.theaustralian.com.au/business/p...h.NZDul4Uv.dpuf
  10. I would strongly suggest you get a complete copy of "Statin Nation". This covers much of what the ABC Catalyst program has/will show. I congratulate the ABC and the presenter for having the courage to present what many of us have known for years. You can see the start of the backlash already. You can view the first 13 minutes of Statin Nation here: http://www.youtube.com/watch?v=Ry1Z8buyd8I For a properly referenced review of the literature see: http://chriskresser.com/the-diet-heart-myt...t-heart-disease And for the latest ie. last week in the British Medical Journal , see: http://www.bmj.com/content/347/bmj.f6340 Cheers Red
  11. Either way Citi have done their credibility a lot of damage. No one would trust them after this.
  12. Yes, I think someone at Citi will not be getting a Christmas bonus. If I sold any shares on the basis of their downgrade I would be very very unhappy witth them. The rational for the downgrade was that they have had a good run and it will not continue. How wrong can you be! Red
  13. Citi downgraded from neutral to sell
  14. 3% drop due to a broker downgrade apparently. Anyone know why?
  15. Some progress on IVIG treatment for Alzheimer's. Ongoing tests over the parst 5-10 years now showing good results. Could be a huge earner for CSL. Some news today: http://www.smh.com.au/business/buccaneer-e...0718-22akj.html Red
×
×
  • Create New...